SIGA Technologies (SIGA) is back in focus after its 2025 earnings release, which showed lower annual revenue and net income, alongside ongoing contracts for TPOXX, pediatric development funding, and ...
SIGA Technologies, Inc. recently reported its fourth quarter and full-year 2025 results, with full-year revenue of US$94.57 million and net income of US$23.28 million, but a sharp year-on-year drop in ...
Generated TPOXX Product Revenues of $88 Million in 2025 Received $13 Million International Procurement Order for Oral TPOXX in January 2026 ...
5don MSN
SIGA outlines continued TPOXX global expansion and expects EMA smallpox decision in March 2026
Q4 2025 Management View CEO Diem Nguyen noted a continued focus on supporting governments globally in preparedness for biological threats, especially smallpox, with SIGA serving "as the leading ...
About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary ...
It’s déjà vu for Siga Technologies and its smallpox antiviral Tpoxx. At an interim analysis of a second mpox trial, the drug again missed the mark on a key measure of disease resolution. In patients ...
Senior execs at SIGA Technologies, controlled by Ron Perelman (pictured), dumped millions in shares after learning its $2.8B government contract was in jeopardy. Jeff Day Executives at a New York ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results